Search
  • 網站搜尋
亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

Human Induced Pluripotent Stem Cells


詳細技術說明

ApplicationHuman induced pluripotent stem cells useful for human stem cell biology, Lesch-Nyhan disease or DYT1 dystonia.Technical SummaryLesch-Nyhan syndrome (juvenile gout) is a rare, inherited disorder caused by deficiency in hypoxanthine-guanine phosphoribosyltransferase (HGPRT). The disease causes overproduction of uric acid often leading to gout and kidney problems. It also causes intellectual and neurological disability. Treatment is symptom-focused and may include use of allopurinol to control overproduction of uric acid as well as extracorporeal shock wave lithotripsy for kidney stones. No treatment for the neurological problems exists.DYT1 dystonia is early onset and typically presents in childhood. It is caused by mutations in the TOR1A gene, which encodes torsinA. While there is no known cure, some patients respond to deep brain stimulation surgery.Researchers have developed human induced pluripotent stem cells (hiPSCs) from normal, healthy volunteers, patients with Lesch-Nyhan disease or DYT1 dystonia. These cells can be used for studying human stem cell biology, Lesch-Nyhan disease or DYT1 dystonia.Developmental StageStem cells are available for license.


國家/地區

美國

欲了解更多信息,請點擊 這裡
Business of IP Asia Forum
桌面版